Analyst Research
| Report Title | Price |
|---|---|
|
Trading Report for (CVS). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
CVS Caremark Corporation Raises FY 2012 EPS Guidance; Issues Q2 2012 EPS Guidance In Line With Analysts' Estimates
CVS Caremark Corporation announced that it raised fiscal 2012 adjusted EPS guidance to $3.23 to $3.33 and GAAP diluted EPS from continuing operations guidance to $3.01 to $3.11. For the second quarter of 2012, it expects adjusted EPS of $0.78 to $0.80 and GAAP diluted EPS from continuing operations guidance of $0.72 to $0.74. According to I/B/E/S Estimates, analysts were expecting the Company to report EPS of $0.73 for second quarter of 2012 and EPS of $3.27 for fiscal 2012.
Latest Developments for CVS Caremark Corp
- Cvs Caremark Corp Reaffirms FY 2013 EPS Guidance-Conference Call
- Cvs Caremark Corp Raises Low End Of Prior FY 2013 EPS Guidance To A Range In Line With Analysts' Estimates; Issues Q2 2013 EPS Guidance In Line With Analysts' Estimates
- Cvs Caremark Corp Buys Drogaria Onofre-Reuters
- Cvs Caremark Corp Raises FY 2013 EPS Guidance
- Share this
- Link this
- Digg this
Follow Reuters